hematopoietic malignancy
Conditions
Interventions
In our institution, total body irradiation are performed as preparative regimen for hematopoietic stem cell transplantation by intensity-modulated radiation therapy. Prescribed dose is 12 Gy in 6 fra
Sponsors
The University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Undergoing hematopoietic stem cell transplantation by myeloablative preparation. Performance status is from 0 to 2. With informed consent. If the patient is underage, we obtain informed consent from parent or legal representation.
Exclusion criteria
Exclusion criteria: With serious complication. With simultaneous double cancer or heterochronic double cancer in last 5 years. With previous history of radiation. Not being able to remain at rest during treatment. With technical problem for intensity-modulated radiation therapy. Being in pregnancy. Judging inadequate by any medical, psychological or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of grade 3 or worse adverse events, based on CTCAE ver. 4.0, from 3 months to 1 year after total body irradiation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reccurence-free survial, overall survival, graft survival rate, time to graft survival, and frequency of grade 3 or worse adverse events in full observation period. | — |
Countries
Japan
Contacts
Public ContactRyosuke TAKENAKA
The University of Tokyo Hospital The department of Radiology
Outcome results
None listed